(LMAT) LeMaitre Vascular - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5255582018
Stock: Grafts, Catheters, Patches, Implants, Biologics
Total Rating 63
Risk 82
Buy Signal -0.14
| Risk 5d forecast | |
|---|---|
| Volatility | 33.0% |
| Relative Tail Risk | -8.52% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.66 |
| Alpha | 13.38 |
| Character TTM | |
|---|---|
| Beta | 0.755 |
| Beta Downside | 1.516 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.32% |
| CAGR/Max DD | 0.88 |
EPS (Earnings per Share)
Revenue
Description: LMAT LeMaitre Vascular March 04, 2026
LeMaitre Vascular, Inc. (LMAT) develops, manufactures, and markets medical devices and implants for vascular surgery. The companys product portfolio includes allografts, embolectomy and thrombectomy catheters, and various biologic patches and grafts. This range covers applications from blood clot removal to vessel and heart repair.
The company operates in the Health Care Equipment sector, which is characterized by specialized product development and regulatory oversight. LeMaitre Vascular utilizes both a direct sales force and distributors to market its products globally.
Further research on platforms like ValueRay can provide deeper insights into LMATs market position and financial performance.
Headlines to watch out for
- Vascular surgery device demand drives revenue growth
- Allograft and biologic patch sales impact top line
- Regulatory approvals for new devices expand market access
- Direct sales force effectiveness influences market penetration
- Healthcare spending trends affect product adoption
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 57.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 5.36 > 1.0 |
| NWC/Revenue: 173.0% < 20% (prev 169.0%; Δ 4.03% < -1%) |
| CFO/TA 0.13 > 3% & CFO 81.3m > Net Income 57.7m |
| Net Debt (157.3m) to EBITDA (90.8m): 1.73 < 3 |
| Current Ratio: 12.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (23.0m) vs 12m ago 0.29% < -2% |
| Gross Margin: 71.53% > 18% (prev 0.69%; Δ 7.08k% > 0.5%) |
| Asset Turnover: 42.76% > 50% (prev 39.84%; Δ 2.91% > 0%) |
| Interest Coverage Ratio: 15.50 > 6 (EBITDA TTM 90.8m / Interest Expense TTM 5.18m) |
Altman Z'' 7.37
| A: 0.70 (Total Current Assets 468.2m - Total Current Liabilities 36.3m) / Total Assets 615.7m |
| B: 0.30 (Retained Earnings 184.7m / Total Assets 615.7m) |
| C: 0.14 (EBIT TTM 80.4m / Avg Total Assets 583.8m) |
| D: 0.82 (Book Value of Equity 182.5m / Total Liabilities 222.2m) |
| Altman-Z'' Score: 7.37 = AAA |
Beneish M -3.10
| DSRI: 0.98 (Receivables 33.6m/30.1m, Revenue 249.6m/219.9m) |
| GMI: 0.96 (GM 71.53% / 68.63%) |
| AQI: 0.87 (AQ_t 0.17 / AQ_t-1 0.20) |
| SGI: 1.14 (Revenue 249.6m / 219.9m) |
| TATA: -0.04 (NI 57.7m - CFO 81.3m) / TA 615.7m) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of LMAT shares?
As of March 22, 2026, the stock is trading at USD 106.31 with a total of 680,422 shares traded.
Over the past week, the price has changed by -1.62%, over one month by +14.65%, over three months by +26.09% and over the past year by +25.21%.
Over the past week, the price has changed by -1.62%, over one month by +14.65%, over three months by +26.09% and over the past year by +25.21%.
Is LMAT a buy, sell or hold?
LeMaitre Vascular has received a consensus analysts rating of 3.73.
Therefor, it is recommend to hold LMAT.
- StrongBuy: 3
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LMAT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 111 | 4.4% |
| Analysts Target Price | 111 | 4.4% |
LMAT Fundamental Data Overview March 21, 2026
P/E Trailing = 43.254
P/E Forward = 37.7358
P/S = 9.9472
P/B = 6.3085
P/EG = 3.148
Revenue TTM = 249.6m USD
EBIT TTM = 80.4m USD
EBITDA TTM = 90.8m USD
Long Term Debt = 168.6m USD (from longTermDebt, last quarter)
Short Term Debt = 2.94m USD (from shortTermDebt, last quarter)
Debt = 185.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 157.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.31b USD (2.48b + Debt 185.6m - CCE 359.1m)
Interest Coverage Ratio = 15.50 (Ebit TTM 80.4m / Interest Expense TTM 5.18m)
EV/FCF = 31.01x (Enterprise Value 2.31b / FCF TTM 74.5m)
FCF Yield = 3.22% (FCF TTM 74.5m / Enterprise Value 2.31b)
FCF Margin = 29.83% (FCF TTM 74.5m / Revenue TTM 249.6m)
Net Margin = 23.13% (Net Income TTM 57.7m / Revenue TTM 249.6m)
Gross Margin = 71.53% ((Revenue TTM 249.6m - Cost of Revenue TTM 71.1m) / Revenue TTM)
Gross Margin QoQ = 71.66% (prev 75.28%)
Tobins Q-Ratio = 3.75 (Enterprise Value 2.31b / Total Assets 615.7m)
Interest Expense / Debt = 0.70% (Interest Expense 1.30m / Debt 185.6m)
Taxrate = 23.24% (4.72m / 20.3m)
NOPAT = 61.7m (EBIT 80.4m * (1 - 23.24%))
Current Ratio = 12.89 (Total Current Assets 468.2m / Total Current Liabilities 36.3m)
Debt / Equity = 0.47 (Debt 185.6m / totalStockholderEquity, last quarter 393.5m)
Debt / EBITDA = 1.73 (Net Debt 157.3m / EBITDA 90.8m)
Debt / FCF = 2.11 (Net Debt 157.3m / FCF TTM 74.5m)
Total Stockholder Equity = 370.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.89% (Net Income 57.7m / Total Assets 615.7m)
RoE = 15.58% (Net Income TTM 57.7m / Total Stockholder Equity 370.7m)
RoCE = 14.90% (EBIT 80.4m / Capital Employed (Equity 370.7m + L.T.Debt 168.6m))
RoIC = 11.45% (NOPAT 61.7m / Invested Capital 539.0m)
WACC = 8.13% (E(2.48b)/V(2.67b) * Re(8.70%) + D(185.6m)/V(2.67b) * Rd(0.70%) * (1-Tc(0.23)))
Discount Rate = 8.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.13%
[DCF] Terminal Value 80.83% ; FCFF base≈59.5m ; Y1≈73.5m ; Y5≈125.1m
[DCF] Fair Price = 83.48 (EV 2.06b - Net Debt 157.3m = Equity 1.90b / Shares 22.8m; r=8.13% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 93.98 | EPS CAGR: 27.93% | SUE: 0.76 | # QB: 0
Revenue Correlation: 96.63 | Revenue CAGR: 13.90% | SUE: 1.33 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.75 | Chg7d=+0.090 | Chg30d=+0.087 | Revisions Net=+6 | Analysts=8
EPS current Year (2026-12-31): EPS=2.89 | Chg7d=+0.298 | Chg30d=+0.298 | Revisions Net=+8 | Growth EPS=+14.5% | Growth Revenue=+11.8%
EPS next Year (2027-12-31): EPS=3.16 | Chg7d=+0.320 | Chg30d=+0.325 | Revisions Net=+6 | Growth EPS=+9.4% | Growth Revenue=+8.6%
[Analyst] Revisions Ratio: +1.00 (6 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.4% (Discount Rate 8.7% - Earnings Yield 2.3%)
[Growth] Growth Spread = +4.5% (Analyst 10.9% - Implied 6.4%)
P/E Forward = 37.7358
P/S = 9.9472
P/B = 6.3085
P/EG = 3.148
Revenue TTM = 249.6m USD
EBIT TTM = 80.4m USD
EBITDA TTM = 90.8m USD
Long Term Debt = 168.6m USD (from longTermDebt, last quarter)
Short Term Debt = 2.94m USD (from shortTermDebt, last quarter)
Debt = 185.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 157.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.31b USD (2.48b + Debt 185.6m - CCE 359.1m)
Interest Coverage Ratio = 15.50 (Ebit TTM 80.4m / Interest Expense TTM 5.18m)
EV/FCF = 31.01x (Enterprise Value 2.31b / FCF TTM 74.5m)
FCF Yield = 3.22% (FCF TTM 74.5m / Enterprise Value 2.31b)
FCF Margin = 29.83% (FCF TTM 74.5m / Revenue TTM 249.6m)
Net Margin = 23.13% (Net Income TTM 57.7m / Revenue TTM 249.6m)
Gross Margin = 71.53% ((Revenue TTM 249.6m - Cost of Revenue TTM 71.1m) / Revenue TTM)
Gross Margin QoQ = 71.66% (prev 75.28%)
Tobins Q-Ratio = 3.75 (Enterprise Value 2.31b / Total Assets 615.7m)
Interest Expense / Debt = 0.70% (Interest Expense 1.30m / Debt 185.6m)
Taxrate = 23.24% (4.72m / 20.3m)
NOPAT = 61.7m (EBIT 80.4m * (1 - 23.24%))
Current Ratio = 12.89 (Total Current Assets 468.2m / Total Current Liabilities 36.3m)
Debt / Equity = 0.47 (Debt 185.6m / totalStockholderEquity, last quarter 393.5m)
Debt / EBITDA = 1.73 (Net Debt 157.3m / EBITDA 90.8m)
Debt / FCF = 2.11 (Net Debt 157.3m / FCF TTM 74.5m)
Total Stockholder Equity = 370.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.89% (Net Income 57.7m / Total Assets 615.7m)
RoE = 15.58% (Net Income TTM 57.7m / Total Stockholder Equity 370.7m)
RoCE = 14.90% (EBIT 80.4m / Capital Employed (Equity 370.7m + L.T.Debt 168.6m))
RoIC = 11.45% (NOPAT 61.7m / Invested Capital 539.0m)
WACC = 8.13% (E(2.48b)/V(2.67b) * Re(8.70%) + D(185.6m)/V(2.67b) * Rd(0.70%) * (1-Tc(0.23)))
Discount Rate = 8.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.13%
[DCF] Terminal Value 80.83% ; FCFF base≈59.5m ; Y1≈73.5m ; Y5≈125.1m
[DCF] Fair Price = 83.48 (EV 2.06b - Net Debt 157.3m = Equity 1.90b / Shares 22.8m; r=8.13% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 93.98 | EPS CAGR: 27.93% | SUE: 0.76 | # QB: 0
Revenue Correlation: 96.63 | Revenue CAGR: 13.90% | SUE: 1.33 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.75 | Chg7d=+0.090 | Chg30d=+0.087 | Revisions Net=+6 | Analysts=8
EPS current Year (2026-12-31): EPS=2.89 | Chg7d=+0.298 | Chg30d=+0.298 | Revisions Net=+8 | Growth EPS=+14.5% | Growth Revenue=+11.8%
EPS next Year (2027-12-31): EPS=3.16 | Chg7d=+0.320 | Chg30d=+0.325 | Revisions Net=+6 | Growth EPS=+9.4% | Growth Revenue=+8.6%
[Analyst] Revisions Ratio: +1.00 (6 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.4% (Discount Rate 8.7% - Earnings Yield 2.3%)
[Growth] Growth Spread = +4.5% (Analyst 10.9% - Implied 6.4%)